• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will Russell Index Removals and New Rett Data Change Taysha Gene Therapies' (TSHA) Narrative?

    Simply Wall St·07/08/2026 07:34:11
    Listen to the news
    • In late June 2026, Taysha Gene Therapies, Inc. was removed from several Russell equity and growth indices while also unveiling new longer-term clinical data for its TSHA-102 Rett syndrome gene therapy program at the International Rett Syndrome Foundation scientific meeting.
    • This combination of index exclusions and maturing TSHA-102 data, including support for an FDA-backed primary endpoint and multiple regulatory designations, gives investors fresh information on both near-term trading dynamics and the longer-term development path.
    • Next, we will examine how the Russell index removals and evolving TSHA-102 Rett syndrome data could reshape Taysha’s investment narrative.

    Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

    Taysha Gene Therapies Investment Narrative Recap

    To own Taysha Gene Therapies, you need to believe TSHA-102 can eventually move from promising Rett data to regulatory approval while the company manages ongoing losses and funding needs. The Russell index removals may affect near term trading and liquidity but do not directly change the key clinical catalyst, which remains upcoming TSHA-102 readouts and regulatory milestones. The biggest current risk is that lengthy, expensive trials and regulatory reviews stretch cash resources before commercialization.

    The most relevant announcement here is the longer term TSHA-102 REVEAL data, including support for the FDA backed developmental milestone assessment primary endpoint. This strengthens the clinical framework just as Taysha exits several Russell indices, giving you more grounding for judging TSHA-102’s path toward a potential BLA filing even as ownership shifts. How those maturing data and index changes interact with future financing and trial costs will be critical.

    Yet behind the promising Rett data, investors should be aware that continued net losses and cash needs could still...

    Read the full narrative on Taysha Gene Therapies (it's free!)

    Taysha Gene Therapies' narrative projects $233.1 million revenue and $44.1 million earnings by 2029. This requires 214.8% yearly revenue growth and a $174.0 million earnings increase from -$129.9 million today.

    Uncover how Taysha Gene Therapies' forecasts yield a $12.85 fair value, a 98% upside to its current price.

    Exploring Other Perspectives

    TSHA 1-Year Stock Price Chart
    TSHA 1-Year Stock Price Chart

    Some of the most optimistic analysts had been assuming TSHA revenue could reach about US$153.4 million by 2028 and earnings about US$24.6 million, which is far more upbeat than consensus. In light of the index removals and evolving TSHA-102 dataset, you may find their focus on trial execution risk and regulatory scrutiny either reassuring or excessive, so it is worth comparing how your own expectations stack up against these very different views.

    Explore 3 other fair value estimates on Taysha Gene Therapies - why the stock might be worth over 9x more than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Contemplating Other Strategies?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.